Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel PH, Maslyar DJ, Jinga V.

Clin Cancer Res. 2019 Feb 1;25(3):928-936. doi: 10.1158/1078-0432.CCR-18-0981. Epub 2018 Jul 23.

PMID:
30037818
2.

Infected hydronephrosis: can we reduce patient suffering and costs?

Pricop C, Puia D, Mereuta O, Ciuta C, Todosi L, Orsolya M, Radavoi GD.

J Pak Med Assoc. 2016 Nov;66(11):1372-1377.

3.

A comprehensive analysis of genome-wide association studies to identify prostate cancer susceptibility loci for the Romanian population.

Rădăvoi GD, Pricop C, Jinga V, Mateş D, Rădoi VE, Jinga M, Ursu RI, Bratu OG, Mischianu DL, Iordache P.

Rom J Morphol Embryol. 2016;57(2):467-75.

4.

Transarterial embolization of renal vascular lesions after percutaneous nephrolithotomy.

Jinga V, Dorobat B, Youssef S, Radavoi GD, Braticevici B, Filipoiu F, Balgradean M.

Chirurgia (Bucur). 2013 Jul-Aug;108(4):521-9.

Supplemental Content

Loading ...
Support Center